Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis

Kopperuncholan Namachivayam, Krishnan MohanKumar, Darla R. Shores, Sunil K. Jain, Jennifer Fundora, Allen D. Everett, Ling He, Hua Pan, Samuel A. Wickline, Akhil Maheshwari

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Necrotizing enterocolitis (NEC) is an inflammatory bowel necrosis of premature infants and an orphan disease with no specific treatment. Most patients with confirmed NEC develop moderate-severe thrombocytopenia requiring one or more platelet transfusions. Here we used our neonatal murine model of NEC-related thrombocytopenia to investigate mechanisms of platelet depletion associated with this disease [K. Namachivayam, K. MohanKumar, L. Garg, B. A. Torres, A. Maheshwari, Pediatr. Res. 81, 817-824 (2017)]. In this model, enteral administration of immunogen trinitrobenzene sulfonate (TNBS) in 10-d-old mouse pups produces an acute necrotizing ileocolitis resembling human NEC within 24 h, and these mice developed thrombocytopenia at 12 to 15 h. We hypothesized that platelet activation and depletion occur during intestinal injury following exposure to bacterial products translocated across the damaged mucosa. Surprisingly, platelet activation began in our model 3 h after TNBS administration, antedating mucosal injury or endotoxinemia. Platelet activation was triggered by thrombin, which, in turn, was activated by tissue factor released from intestinal macrophages. Compared to adults, neonatal platelets showed enhanced sensitivity to thrombin due to higher expression of several downstream signaling mediators and the deficiency of endogenous thrombin antagonists. The expression of tissue factor in intestinal macrophages was also unique to the neonate. Targeted inhibition of thrombin by a nanomedicine-based approach was protective without increasing interstitial hemorrhages in the inflamed bowel or other organs. In support of these data, we detected increased circulating tissue factor and thrombin-antithrombin complexes in patients with NEC. Our findings show that platelet activation is an important pathophysiological event and a potential therapeutic target in NEC.

Original languageEnglish (US)
Pages (from-to)10958-10969
Number of pages12
JournalProceedings of the National Academy of Sciences of the United States of America
Volume117
Issue number20
DOIs
StatePublished - May 19 2020

Keywords

  • Coagulation
  • Inflammation
  • Intestinal

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis'. Together they form a unique fingerprint.

  • Cite this

    Namachivayam, K., MohanKumar, K., Shores, D. R., Jain, S. K., Fundora, J., Everett, A. D., He, L., Pan, H., Wickline, S. A., & Maheshwari, A. (2020). Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis. Proceedings of the National Academy of Sciences of the United States of America, 117(20), 10958-10969. https://doi.org/10.1073/pnas.1912357117